Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9DMH

Human muscle nAChR ACh-bound state

Summary for 9DMH
Entry DOI10.2210/pdb9dmh/pdb
EMDB information47005
DescriptorAcetylcholine receptor subunit alpha, ACETYLCHOLINE, (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate, ... (12 entities in total)
Functional Keywordshuman muscle, nicotinic acetylcholine receptor, membrane protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains5
Total formula weight281705.38
Authors
Li, H.,Hibbs, R.E. (deposition date: 2024-09-13, release date: 2025-04-09, Last modification date: 2025-10-22)
Primary citationLi, H.,Pham, M.C.,Teng, J.,O'Connor, K.C.,Noviello, C.M.,Hibbs, R.E.
Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures.
Cell, 188:2390-2406.e20, 2025
Cited by
PubMed Abstract: Skeletal muscle contraction is triggered by acetylcholine (ACh) binding to its ionotropic receptors (AChRs) at neuromuscular junctions. In myasthenia gravis (MG), autoantibodies target AChRs, disrupting neurotransmission and causing muscle weakness. While treatments exist, variable patient responses suggest pathogenic heterogeneity. Progress in understanding the molecular basis of MG has been limited by the absence of structures of intact human muscle AChRs. Here, we present high-resolution cryoelectron microscopy (cryo-EM) structures of the human adult AChR in different functional states. Using six MG patient-derived monoclonal antibodies, we mapped distinct epitopes involved in diverse pathogenic mechanisms, including receptor blockade, internalization, and complement activation. Electrophysiological and binding assays revealed how these autoantibodies directly inhibit AChR channel activation. These findings provide critical insights into MG immunopathogenesis, uncovering unrecognized antibody epitope diversity and modes of receptor inhibition, and provide a framework for developing personalized therapies targeting antibody-mediated autoimmune disorders.
PubMed: 40203823
DOI: 10.1016/j.cell.2025.03.004
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.06 Å)
Structure validation

244349

건을2025-11-05부터공개중

PDB statisticsPDBj update infoContact PDBjnumon